Two phase II clinical studies evaluating the combined use of PD‐1 inhibitors with EGFR inhibitors have shown that the combination of pembrolizumab or nivolumab with cetuximab exhibits promising efficacy and safety in R/M‐HNSCC, demonstrating its potential as a first‐line treatment option [84, 85]. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.